Accelerating Lung Cancer Diagnosis Through Liquid Biopsy (ACCELERATE)

University Health Network, Toronto

Status: Active, not recruiting

Conditions: Non-small Cell Lung Cancer

Treatments: Diagnostic Test: Liquid Biopsy

Study type: Observational

Funder types: Other

Identifiers

NCT04863924

20-5915

Details and patient eligibility

About

This study will assess the utility of liquid biopsy to accelerate the time to treatment for patients with newly diagnosed advanced non-small cell lung cancer, compared to the conventional diagnostic pathway of molecular testing of tumour tissue after imaging and biopsy.

Enrollment: 170 patients

Sex: All

Ages: 18+ years old

Volunteers: No Healthy Volunteers

Inclusion criteria

1. Lung RAMP Multidisciplinary Cancer Conference or study team confirms radiologic (clinical) evidence of advanced, unresectable lung cancer;
2. Measurable disease (presumed malignant) by RECIST 1.1;
3. Age ≥18 years;
4. Ability to provide written informed consent;
5. Diagnostic biopsy and molecular profiling ordered or planned. Patients remain eligible even if biopsy or tumour testing later fails or is deemed not feasible.

Exclusion criteria

1. Pregnancy;
2. Concurrent active malignancy except for localized non-melanomatous skin cancer or non-invasive cervical cancer. Any previous cancer (excluding NSCLC) must have been treated more than 2 years prior to study entry with no current evidence of active disease.

Trial design

170 participants in 1 patient group

Advanced NSCLC

Description:

Patients with radiologic evidence of advanced (unresectable stage III or IV) non-small cell lung cancer

Treatment:

Diagnostic Test: Liquid Biopsy